However, if anti-VEGF drugs, as bevacizumab, or multi-targeted receptor tyrosine kinase inhibitors, as sunitinib, have shown proven efficacy towards sporadic forms of cerebellar hemangioma, pancreatic NETs and RCC, a specific role of these agents in VHL patients, although used, is less clear [32]. The gene discussed is NTRK1; the disease is pancreatic neuroendocrine tumor.